Explore the Efficacy and Safety of Once-Daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Non-Valvular Atrial Fibrillation Scheduled for Cardioversion - X-VeRT


Vitamin K antagonists are the standard of care before and after DC cardioversion for atrial fibrillation; however, this poses logistical issues for some patients. The goal of the trial was to evaluate treatment with the novel oral anticoagulant, rivaroxaban, compared with vitamin K antagonists among participants undergoing cardioversion for atrial fibrillation.